返回
Molnupiravir: coding for catastrophe
DOI:10.1038/s41594-021-00657-8.png)
摘要
En 中文
Molnupiravir, a wide-spectrum antiviral that is currently in phase 2/3 clinical trials for the treatment of COVID-19, is proposed to inhibit viral replication by a mechanism known as 'lethal mutagenesis'. Two recently published studies reveal the biochemical and structural bases of how molnupiravir disrupts the fidelity of SARS-CoV-2 genome replication and prevents viral propagation by fostering error accumulation in a process referred to as 'error catastrophe'.
期刊
N
IF:
10.1
论文数:
4.8K
被引数:
2.8W
机构
引用论文
Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses流感和呼吸道合胞病毒的口服有效广谱核糖核苷类似物抑制剂
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice口服生物可利用的广谱抗病毒药物抑制小鼠人类气道上皮细胞培养物和多种冠状病毒的SARS-CoV-2
Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia在雪貂和人类气道上皮中具有高抗性屏障的口服有效流感药物的特征
β-D-N4-Hydroxycytidine Is a Potent Anti-alphavirus Compound That Induces a High Level of Mutations in the Viral GenomeΒ-d-n4-羟基胞苷是一种有效的抗甲病毒化合物,可诱导病毒基因组发生高水平的突变
JOURNAL OF VIROLOGY
IF3.8
Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit美国国立卫生研究院SARS-CoV-2抗病毒治疗峰会的报告
Small-Molecule Antiviral β-D-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance小分子抗病毒 β-d-n4-羟基胞苷抑制校对完整的冠状病毒,具有很高的抗性遗传屏障
JOURNAL OF VIROLOGY
IF3.8

